The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 695K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

19 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).EBI
Novartis Institute For Biomedical Research
Structure-based design and optimization of potent inhibitors of the adenoviral protease.EBI
Novartis Institute For Biomedical Research
Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway.EBI
Novartis Institute For Biomedical Research
Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.EBI
Novartis Institute For Biomedical Research
1-Aminomethylisoquinoline-4-carboxylates as novel dipeptidylpeptidase IV inhibitors.EBI
Novartis Institute For Biomedical Research
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.EBI
Novartis Institute For Biomedical Research
A novel Pd-catalyzed cyclization reaction of ureas for the synthesis of dihydroquinazolinone p38 kinase inhibitors.EBI
Novartis Institute For Biomedical Research
1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.EBI
Novartis Institute For Biomedical Research
1,4-Diazepane-2-ones as novel inhibitors of LFA-1.EBI
Novartis Institute For Biomedical Research
Synthesis and biological activity of potent heterocyclic thiol-based inhibitors of endothelin-converting enzyme-1.EBI
Novartis Institute For Biomedical Research
Design and synthesis of potent and selective inhibitors of integrin VLA-4.EBI
Novartis Institute For Biomedical Research
Isoindolines: a new series of potent and selective endothelin-A receptor antagonists.EBI
Novartis Institute For Biomedical Research
Synthesis and biological activity of novel potent endothelin-converting enzyme-1 inhibitors.EBI
Novartis Institute For Biomedical Research
Design and synthesis of potent thiol-based inhibitors of endothelin converting enzyme-1.EBI
Novartis Institute For Biomedical Research
Scaffold Morphing Identifies 3-Pyridyl Azetidine Ureas as Inhibitors of Nicotinamide Phosphoribosyltransferase (NAMPT).EBI
Novartis Institute For Biomedical Research
N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).EBI
Novartis Institute For Biomedical Research
Secondary amides of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase.EBI
Novartis Institute For Biomedical Research
Anilides of (R)-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase.EBI
Novartis Institute For Biomedical Research
(R)-3,3,3-Trifluoro-2-hydroxy-2-methylpropionamides are orally active inhibitors of pyruvate dehydrogenase kinase.EBI
Novartis Institute For Biomedical Research